Biosite Diagnostics' cardiac panel gets green light:
This article was originally published in Clinica
The FDA has given a 510(k) marketing clearance to Biosite Diagnostics' Triage Cardiac Panel. The panel provides rapid simultaneous quantitative measurement of three important biochemical markers for heart attacks and is used in conjunction with the Triage Meter. Prior to selling the cardiac panel, the company will be required to obtain clearance for two additional 510(k)'s, related to test quality control and calibration, and another for the Triage Meter.
You may also be interested in...
COVID-19 Vaccines: ACIP’s Allocation Proposal Prioritizes Long-Term Care Residents, Essential Workers
First group to receive vaccine would comprise health care personnel and residents of long-term care facilities; next in line are non-health care essential workers, who would take priority over adults with high-risk medical conditions and those ages 65 years and older, according to the CDC advisory committee’s proposed allocation framework.
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.